Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
PDX1328 Volasertib
0.0001
PLK
Cell cycle
 1.0793 0.00822
Hs 578T Dinaciclib
0.0001
pan CDK
Cell cycle
 0.9649 0.00169
T47D Dinaciclib
0.0001
pan CDK
Cell cycle
 0.9929 0.00094
T47D Taxol
0.0001
Chemo
Chemotherapy
 0.9933 0.01216
T47D Luminespib
0.0001
HSP90
Misc
 1.0474 0.00019
Hs 578T Trametinib
0.0001
MEK
MAPK/nRTK
 0.9824 -0.00001
HCC1806 Torin2
0.0001
mTOR/ATM/ATR
PI3K/mTOR
 1.0343 -0.00199
PDX1328 Torin2
0.0001
mTOR/ATM/ATR
PI3K/mTOR
 0.9695 0.00374
PDX1328 Dinaciclib
0.0001
pan CDK
Cell cycle
 1.0810 0.00602
CAMA-1 Trametinib
0.0001
MEK
MAPK/nRTK
 0.9917 -0.00222
MDA-MB-157 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9547 0.00231
MDA-MB-157 Taxol
0.00031623
Chemo
Chemotherapy
 1.0667 0.01003
MDA-MB-231 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9574 0.01575
MDA-MB-157 Luminespib
0.00031623
HSP90
Misc
 1.0143 0.00005
Hs 578T Doxorubicin
0.00031623
Chemo
Chemotherapy
 0.9514 0.00129
MDA-MB-157 Dinaciclib
0.00031623
pan CDK
Cell cycle
 1.0629 -0.00194
MDA-MB-157 Doxorubicin
0.00031623
Chemo
Chemotherapy
 0.9388 0.00482
MDA-MB-231 INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9572 0.00181
MDA-MB-231 Taxol
0.00031623
Chemo
Chemotherapy
 0.9486 0.01025
MDA-MB-134-VI Neratinib
0.00031623
EGFR/HER2
RTK
 1.3354 0.00352
MDA-MB-231 Doxorubicin
0.00031623
Chemo
Chemotherapy
 0.9126 0.00521
HCC1806 Volasertib
0.00031623
PLK
Cell cycle
 1.0541 -0.00368
MDA-MB-134-VI INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9671 -0.00323
MDA-MB-157 Palbociclib
0.00031623
CDK4/6
Cell cycle
 0.9482 0.00160
MDA-MB-157 Volasertib
0.00031623
PLK
Cell cycle
 1.0814 -0.00135